The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.
Abstract
Insulin resistance and dyslipidemia have been described in women with polycystic ovary syndrome (PCOS), a disorder characterized by hyperandrogenism and oligomenorrhea. Although oral contraceptives (OC) are often instituted to regulate menses and suppress HA in women with PCOS, their use has been postulated to cause a deterioration in insulin sensitivity and to adversely affect circulating lipids. To investigate these effects, 9 women with PCOS and 10 age- and weight-matched control women were studied before and during the third month of therapy with a low-dose norethindrone-containing triphasic combination OC using the hyperglycemic clamp technique. At baseline, the PCOS group had higher androgen, triglyceride, and glycosylated hemoglobin concentrations, with a greater insulin response to oral glucose and a lower insulin sensitivity index (ISI) than controls. During OC therapy, a reduction in ISI was observed in both groups, whereas an increase in triglycerides was observed only in controls, removing any observed difference between the two groups in ISI or lipids. In women with PCOS, an increase in insulin concentrations during hyperglycemia accounted for the decline in ISI (P = 0.026), whereas in control women the decrease in ISI was attributable to a decrease in glucose disposal (P = 0.004). In conclusion, PCOS is characterized by insulin resistance in the untreated state. Short-term therapy with a triphasic OC results in a further decline in ISI in women with PCOS, without inducing additional adverse effects on lipids. A more pronounced decline in ISI together with an elevation in triglyceride levels occurs in normal women with OCs. The mechanisms leading to this decrease in ISI are different for each group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COCP does not have any major effects on carbohydrate metabolism in healthy women, whereas the effect on lipid metabolism depends on the level of estrogen and type of progestin, with potential negative effects (78, 79, 80, 81).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [78]
In the citing paper
“COCP does not have any major effects on carbohydrate metabolism in healthy women, whereas the effect on lipid metabolism depends on the level of estrogen and type of progestin, with potential negative effects (78, 79, 80, 81).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [78]
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Quantitative Determination of Serum Triglycerides by the Use of Enzymes
Bucolo, G., & David, H. (1973) · Clinical Chemistry · doi:10.1093/clinchem/19.5.476 · Cited by 3,184
Clinical assessment of body hair growth in women.
Ferriman, D., & Gallwey, J. D. (1961) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jcem-21-11-1440 · Cited by 2,556
Validation of tetrapolar bioelectrical impedance method to assess human body composition
Lukaski, H. C., Bolonchuk, W. W., Hall, C. B., & Siders, W. A. (1986) · Journal of Applied Physiology · doi:10.1152/jappl.1986.60.4.1327 · Cited by 1,370
Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study
Segal, K., Van Loan, M., Fitzgerald, P., Hodgdon, A., & Van Itallie, T. (1988) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/47.1.7 · Cited by 881
NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Barbieri, R. L., Makris, A., Randall, R. W., Daniels, G. H., Kistner, R. W., & Ryan, K. J. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-5-904 · Cited by 629
Dunaif, A. E., GRAF, M., Mandeli, J., Laumas, V., & Dobrjansky, A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-3-499 · Cited by 577
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417
Cited by
Sorted by citations
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Dunaif, A. E. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,776
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Treatment options for polycystic ovary syndrome
Badawy, A., & Elnashar (2011) · International Journal of Women s Health · doi:10.2147/ijwh.s11304 · Cited by 619
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Leo, V. D., Marca, A. L., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 291
Metadata
- Authors
- Korytkowski, M. T., Mokan, M., Horwitz, M. J., & Berga, S. L.
- Affiliations
- University of Pittsburgh (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-11
- Volume
- 80
- Issue
- 11
- Pages
- 3327-3334
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2113514432
- Cited by
- 140
- References
- 43
- Citations by year
- 2026: 1 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 4 · 2012: 4
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M01RR000056, 5 M01 RR00056, 2S07-RR-0541629)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- polycystic ovary syndrome, oral contraceptives, insulin resistance, insulin sensitivity index, hyperandrogenism, triglycerides, dyslipidemia, norethisterone, glucose disposal, hyperglycemic clamp, hyperinsulinemia
- MeSH terms
- Adult, Contraceptives, Oral, Female, Glucose Tolerance Test, Humans, Lipids, Polycystic Ovary Syndrome, Reference Values, Gonadal Steroid Hormones, Glucose Clamp Technique
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review